SRR8518421
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.560
- E2F_TARGETS+0.530
- G2M_CHECKPOINT+0.470
- MYC_TARGETS_V1+0.410
- MTORC1_SIGNALING+0.350
- UNFOLDED_PROTEIN_RESPONSE+0.300
- MITOTIC_SPINDLE+0.270
- OXIDATIVE_PHOSPHORYLATION+0.270
- UV_RESPONSE_UP+0.270
- GLYCOLYSIS+0.230
Top 10 suppressed
- KRAS_SIGNALING_UP-0.250
- ANDROGEN_RESPONSE-0.230
- ALLOGRAFT_REJECTION-0.220
- BILE_ACID_METABOLISM-0.210
- IL6_JAK_STAT3_SIGNALING-0.210
- COMPLEMENT-0.200
- IL2_STAT5_SIGNALING-0.200
- INFLAMMATORY_RESPONSE-0.200
- PANCREAS_BETA_CELLS-0.190
- TNFA_SIGNALING_VIA_NFKB-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_4SCWT0FX | Ependymoma NOS | — | 0.823 |
| 2 | SRR8518200 | — | E | 0.823 |
| 3 | TCGA-CV-5436-01A-01R-1514-07 | — | — | 0.821 |
| 4 | TCGA-63-A5MJ-01A-11R-A27Q-07 | — | cohortSQ2 | 0.816 |
| 5 | TCGA-77-8009-01A-11R-2187-07 | — | cohortSQ2 | 0.801 |
| 6 | TCGA-A7-A0CE-01A-11R-A00Z-07 | — | E | 0.800 |
| 7 | TCGA-56-A62T-01A-11R-A405-07 | — | cohortSQ1 | 0.799 |
| 8 | ULC0595T_S33 | — | cohortA1 | 0.794 |
| 9 | TCGA-CR-6493-01A-11R-1873-07 | — | — | 0.787 |
| 10 | MNG618 | — | — | 0.782 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.560 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.530 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.470 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.410 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.350 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.300 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.270 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.270 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.270 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.230 | Inavolisib | — uncovered |
| MYOGENESIS | 0.230 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.220 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.220 | Inavolisib | — uncovered |
| HYPOXIA | 0.160 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.150 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.140 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.130 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.110 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.110 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.080 | Remibrutinib | — uncovered |